Login to Your Account



ImClone Considering Sale; Erbitux Growth Continues

By Karen Pihl-Carey


Wednesday, January 25, 2006
Despite a market cap of close to $3 billion and a 58 percent increase in Erbitux revenues in 2005, ImClone Systems Inc. is exploring strategic options that could include the sale of the company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription